China Mengniu Dairy Shares Fall on Profit Miss
By Amanda Lee
China Mengniu Dairy shares fell by the most in almost two years after annual profit fell short of expectations.
Shares of Mengniu, one of China's largest dairy companies, were 7.5% lower at 17.50 Hong Kong dollars (US$2.24) in Wednesday morning trade, extending year-to-date losses to 16%. The slide puts the stock on track for its biggest one-day percentage drop since October 2022.
Mengniu said late Tuesday that 2023 net profit fell 9.3% to 4.81 billion yuan (US$666.4 million), partly due to higher expenses, including a write-down of raw material inventories. That was short of a consensus estimate of CNY5.20 billion by a FactSet poll of analysts.
Revenue rose 6.5% to CNY98.62 billion, slightly ahead of expectations, on the back of higher sales in the liquid milk and ice cream segments.
Citi analysts kept a buy rating on Mengniu, highlighting EBIT margin improvement and an "upside surprise" in a higher dividend payout ratio against the profit miss. They have a HK$31.90 target price on the stock.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
March 27, 2024 00:10 ET (04:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Will the CPI Allow the Fed to Cut Rates in September?
-
Dozens of Stocks Are Newly Undervalued After Market Selloff
-
Where to Invest During the Stock Market Rotation
-
What’s Happening in the Markets This Week
-
Now’s the Time to Diversify Beyond the ‘Magnificent Seven’ Stocks
-
Don’t Let Recency Bias Lead You Astray
-
AI Could Bring a ‘New Wave of Globalization’—and Security Risks
-
Here’s What Sparked Monday’s Stock Market Madness
-
Paramount Earnings: Streaming Strength and Cost-Savings Plan Overshadow Revenue Weakness
-
How to Invest Like Warren Buffett
-
Is Arm Stock a Buy After Earnings?
-
Oxy Earnings: Cost-Efficient Production and Low Operating Expenses Create Solid Results
-
After Earnings, Is Berkshire Hathaway Stock a Buy?
-
The Best Healthcare Stocks to Buy
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
Eli Lilly Earnings: Strong Diabetes and Obesity Sales Continue